All In Biotech

Free tool

FAERS Monitor: Edarbi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 200796 or its brand name (Edarbi, Azilsartan Kamedoxomil). Reports on generic versions are filed under their own applications.

Reports

3,052

Serious

2,180

71% of reports

Hospitalization

1,145

Death reported

256

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea169
  • hypertension165
  • drug ineffective135
  • dizziness132
  • nausea131
  • off label use115
  • fatigue113
  • headache106
  • renal impairment100
  • malaise99
  • blood pressure increased97
  • decreased appetite95
  • hypotension87
  • wrong technique in product usage process75
  • vomiting73

Reports by year received

View as table
YearReports
201126
201243
201368
201454
201575
2016166
2017220
2018152
2019168
2020196
2021233
2022386
2023381
2024333
2025355
2026196

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
renal impairmentSignal1008.26.8628
hypertensionSignal1655.44.6588
blood pressure increasedSignal974.43.6251
hypotensionSignal873.02.4114
decreased appetiteSignal952.82.3111
wrong technique in product usage processSignal752.62.070
dizziness1321.81.549
diarrhoea1691.81.662
malaise991.61.320
headache1061.21.02
nausea1311.11.02
vomiting731.10.90
fatigue1131.00.80
off label use1150.90.81
drug ineffective1350.70.617

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.